5 results about "CARCINOMA COLON" patented technology

Disclosed are methods for detecting and treating cancers (such as carcinoma, leukemia, lung cancer, colon cancer, central nervous system (CNS) cancer, melanoma, ovarian cancer, renal cancer, oral cancer, prostate cancer and / or breast cancer). The method may include receiving a sample from a patient (such as a sample from a biopsy, a sample from an extracellular vesicle, or a sample from a circulating tumor cell). The method may include determining whether a LY6C protein or a phosphorylated ANXA2 protein is detected in the sample. The method may include treating a patient for cancer by targeting the LY6C protein when the LY6C protein is detected (e.g., using photoimmunotherapy (PIT) or near infrared photoimmunotherapy (NIR-PIT)). or treating a patient for cancer by targeting an ANXA2 protein (e.g, using inhibitors, decoys, etc.) when the phosphorylated ANXA2 protein is detected.

The application belongs to the technical fields of synthesis of compounds and pharmaceutical applications, and discloses an anti-tumor pterostilbene piperazine conjugate as well as a preparation method and application thereof. The pterostilbene, piperazine and various substituents are spliced in one molecule by using a molecular hybridization method, a novel anti-tumor pterostilbene piperazine conjugate is synthesized, and it is found through anti-tumor activity research that the anti-tumor activity of the conjugate is obviously higher than that of the two pharmacophores alone, and the conjugate has the potential to become a novel anti-tumor drug. The pterostilbene piperazine conjugate is synthesized, and it is found for the first time that the compound has good anti-tumor activity, can significantly inhibit the proliferation of various tumor cells in vitro, including hepatocarcinoma, triple-negative breast cancer, colon cancer and ovarian cancer cells, has little toxicity to normal cells, and can inhibit the migration ability of tumor cells. Therefore, the compound synthesized by the application has good anti-tumor application prospect.

The embodiment of the application discloses a kind of vein bionics microfluidic chip and its preparation and application method of simulating multi-organ interconnection.The chip includes a chip main body, and its microfluid channel system integrates at least three organ simulation units: a lung simulation chamber for culturing lung cells to simulate upstream organs that can produce systemic effects;An upstream colon cancer cell culture chamber for three-dimensional culture of colon cancer cells to simulate tumor primary lesions;And a downstream liver cell culture chamber for three-dimensional co-culture of liver cells and vascular endothelial cells to simulate the target organ of liver, and the three simulation chambers are communicated with each other by a vein bionics microfluid network, which simulates the complex blood circulation system of human body (including pulmonary circulation and systemic circulation), can realize the signal molecule transmission between organs, and simulate the invasion and metastasis process of colon cancer cells to the target organ of liver via the circulatory system after being affected by upstream lung signals.

This invention relates to purine derivative G4-targeting protein chimeras, and more particularly to a class of purine derivative G4-targeting protein chimeras synthesized using PROTAC technology and possessing antitumor activity. The general structural formula of the targeting chimera is as follows: where R is a linker, representing triethylene glycol, tetraethylene glycol, pentaethylene glycol, a four-carbon chain, a five-carbon chain, a six-carbon chain, a seven-carbon chain, an eight-carbon chain, a nine-carbon chain, azacyclobutane, tetrahydropyrrole, piperidine, or 1-phenylpiperazine. Spectroscopic and mass spectrometric data analysis show that the synthesized purine derivative G4-targeting protein chimeras are novel compounds. In vitro antitumor activity studies have demonstrated that the purine derivative G4-targeting protein chimeras provided by this invention exhibit strong antitumor activity against human triple-negative breast cancer cells MDA-MB-231, human gastric adenocarcinoma cells MGC803, human liver cancer cells HepG2, and human colon cancer cells HCT-116. This is an excellent new antitumor compound with the potential to be developed into a new antitumor drug.

The present technology provides compounds, as well as compositions including such compounds, useful for imaging and / or treatment of a glioma, a breast cancer, an adrenal cortical cancer, a cervical carcinoma, a vulvar carcinoma, an endometrial carcinoma, a primary ovarian carcinoma, a metastatic ovarian carcinoma, a non-small cell lung cancer, a small cell lung cancer, a bladder cancer, a colon cancer, a primary, gastric adenocarcinoma, a primary colorectal adenocarcinoma, a renal cell carcinoma, and / or a prostate cancer. The compounds are represented by the following formulaor a pharmaceutically acceptable salt thereof.